Vancomycin dosing in neonatal patients: the controversy continues

Area of Science:

• Neonatal Pharmacology
• Infectious Diseases
• Pediatric Critical Care

Background:

• Increasing incidence of penicillinase-resistant penicillin-resistant staphylococcus necessitates vancomycin use.
• Vancomycin utilization has increased, driving research into optimal dosing for pediatric populations.
• Neonatal vancomycin dosing is complex due to decreased renal clearance and larger volume of distribution.

Purpose of the Study:

• To review and propose effective vancomycin dosing strategies for premature neonates and infants.
• To address the variability in vancomycin pharmacokinetics observed in neonates.
• To guide rational vancomycin dosing based on patient-specific factors.

Main Methods:

• Analysis of vancomycin pharmacokinetics in premature neonates and infants.
• Consideration of postconceptional age (PCA) and gestational age (GA) in dosing.
• Evaluation of factors complicating renal maturation, such as sepsis and respiratory distress syndrome.

Main Results:

• Vancomycin clearance and volume of distribution show variability even with similar postconceptional ages.
• Maturation rates of vancomycin disposition mechanisms appear similar for equal postconceptional ages, irrespective of gestational age.
• Existing vancomycin dosing regimens are often based on retrospective data and physician discretion.

Conclusions:

• Vancomycin dosing regimens for premature neonates and infants must account for postconceptional age (PCA) and body weight.
• Further research is needed to establish evidence-based vancomycin dosing guidelines for this vulnerable population.
• Optimized dosing is crucial for ensuring therapeutic efficacy and minimizing toxicity in neonates.